Biocon's stock increased due to a distribution agreement with Sandoz for Japan's immune jab

 Biocon's stock increased due to a distribution agreement with Sandoz for Japan's immune jab

Biocon's stock increased due to a distribution agreement with Sandoz for Japan's immune jab

A distribution agreement was reached between Biocon Biologics and Sandoz, granting the latter the only authority to market, sell, and distribute subcutaneous injections of adalimumab BS.

Biocon: Biocon Biologics, a subsidiary, and Sandoz inked a distribution deal that grants the former the only authority to market, sell, and provide adalimumab BS for subcutaneous injection in Japan. The worldwide biosimilar portfolio of Viatris, which included adalimumab, was bought by the subsidiary. Affiliate Biocon Biologics Ltd. and medication producer Fujifilm Kyowa Kirin Biologics Co. Ltd. have an exclusive worldwide marketing licensing agreement in place. Immune-related conditions such psoriasis vulgaris, ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis, and Crohn's disease may be treated with adalimumab BS, a biosimilar of Humira.

Following the signing of a distribution agreement between the company's subsidiary and Sandoz for the immune-linked injection in Japan, Biocon shares increased by 1% in early trade on December 26.

On the BSE, Biocon was up Rs 4.20, or 1.71 percent, at Rs 250.40 at 9:32 a.m.

According to a press statement from the firm, Biocon Biologics and Sandoz inked a distribution agreement that grants the former the only authority to market, sell, and distribute adalimumab BS for subcutaneous injection [FKB].

According to the terms of the deal, Viatris will finish the product's marketing and promotion by December 15, 2023, but will continue to assist with the transition until Sandoz progressively takes over management of the product beginning on February 15, 2024. will carry on.

The portfolio of Viatris' worldwide biosimilars, which included adalimumab, was bought by Biocon Biologics.

Fujifilm Kyowa Kirin Biologics Co. Ltd., the drug's developer, and Biocon Biologics Ltd., its partner, have reached an exclusive worldwide marketing licensing deal.

Adalimumab BS [FKB] is a subcutaneous injectable biosimilar to Humira; it is also known by its generic name, adalimumab (genetic recombinant). It is used for immune-related conditions, including ulcerative colitis, psoriasis vulgaris, ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease. has vanished.

The seamless integration of Viatris' biosimilar business, which Biocon Biologics recently bought and expanded into 120 countries, was recently reported.

Biocon Biologics has a robust pipeline consisting of twenty assets in the fields of immunology, ophthalmology, cancer, and diabetology worldwide.